Physician profile
Evan Johnson
NPI 1023547890
$30,283.18
in general payments reported to CMS, 2019-2025
21 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25K · 2022: $1,128 · 2023: $3,252 · 2024: $332 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,414 · Food and Beverage: $1,602 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,414.19 |
| Food and Beverage | $1,601.60 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $26,271.42 | 2021-2025 | Percept PC Brainsense |
| Abbott Laboratories | $2,259.58 | 2023 | Infinity, Proclaim |
| Boston Scientific Corporation | $683.04 | 2022-2023 | |
| Abbvie INC. | $387.78 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $175.59 | 2022-2025 | Austedo Xr |
| Mdd US Operations, LLC | $70.87 | 2023-2025 | Gocovri, Qelbree, Gocovri |
| Ge Healthcare | $69.74 | 2023 | |
| Merz Pharmaceuticals, LLC | $56.79 | 2022-2025 | Inbrija, Xeomin |
| Acorda Therapeutics, INC | $31.57 | 2023 | Inbrija |
| Jazz Pharmaceuticals INC. | $31.08 | 2022 | |
| Genzyme Corporation | $27.59 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.87 | 2022 | |
| Grifols USA, LLC | $24.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.84 | 2022 | |
| Sk Life Science, INC. | $23.65 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $23.54 | 2022 | |
| Neurocrine Biosciences, INC. | $21.24 | 2023 | Ingrezza, Ongentys |
| Insightec,INC | $20.67 | 2025 | Exablate |
| Amneal Pharmaceuticals LLC | $20.03 | 2023 | Rytary |
| Neurelis, INC. | $18.62 | 2023 | Valtoco |
| Acadia Pharmaceuticals INC | $17.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.